Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management

Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management

Abstract Introduction Venetoclax has demonstrated clinical benefit for newly-diagnosed acute myeloid leukemia (AML), but significant neutropenia is a concern. Data on the time course of neutrophil counts for across treatment cycles in real-world settings remain limited. We report an interim analysis...

Full description

Saved in:
Bibliographic Details
Main Authors: Tatsunori Goto, Hiroki Numata, Yuna Katsuoka, Nobuhiko Uoshima, Satoru Hara, Jun Ando, Shuichi Ota, Goichi Yoshimoto, Akihito Matsuoka, Hideyuki Hashiba, Tetsuo Morita, Atsuko Tsutsui, Ryota Imanaka
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Oncology and Therapy
Subjects:
Acute myeloid leukemia
Antifungal
Granulocyte colony-stimulating factor
Neutropenia
Venetoclax
Online Access:https://doi.org/10.1007/s40487-025-00329-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40487-025-00329-3

Similar Items